The user experienced significant hair regrowth after one year on male-to-female hormone replacement therapy (HRT) and nine months using minoxidil and finasteride. They noted a reduction in body hair and attributed much of the hair regrowth to the addition of minoxidil.
User Tricky9555 tried various hair loss treatments for 8 months with no visible results. Others suggested considering a hair transplant, checking thyroid levels, and being patient for up to 24 months for potential results.
KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.
Hair/scalp cloning for unlimited transplants is likely a decade away, with prior transplants not significantly affecting future options. Advances in AI and research in wound-induced hair neogenesis are promising, but infrastructure and technology constraints remain challenges.
The conversation is about someone experiencing slow but steady hair regrowth using topical Minoxidil and 1mg Finasteride daily since mid-December. Another person commented positively on the progress.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
The user experienced hair regrowth after using 5% topical minoxidil for over four months, despite initial shedding. They apply it once daily but occasionally skip days due to concerns about collagen production interference.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
A user's 2.5 year transformation of using 0.5mg finasteride and RU58841 to combat hair loss, with the possibility of increasing the RU for further regrowth.
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
A person shares their 10-month hair loss treatment progress using finasteride 1.25 mg daily, topical minoxidil 5% daily, weekly dermarolling with a 1.5mm device, and RU58841 for one month, encouraging others not to give up despite slow results. They noticed their progress after comparing past photos.
The user "Dekar__" is experiencing a significant shed on Minoxidil 5% foam after 2.5 months of use, with no visible regrowth yet. They are also using Alfatradiol.
Charts show how long Finasteride and Dutasteride stay in the blood, explaining why 0.5 mg Finasteride is less effective than 1 mg. Dutasteride accumulates over time, leading to gradual results compared to the immediate effects of Finasteride.
The conversation is about someone using minoxidil, finasteride, RU58841, and microneedling for hair loss treatment for nearly two years with ongoing improvement. They are questioning the likelihood of continued hair regrowth over a four-year period.
A user shared impressive hair regrowth results after 4 months using topical minoxidil and dutasteride but is concerned about slow-growing baby hairs. Responses suggest patience, as full results can take up to 2 years.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
A user's personal hair loss progress with treatments, including finasteride (1.25mg), minoxidil, needling, and Nizoral; and advice from other users on how to perform the needling correctly.
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.
The conversation is about hair regrowth or miniaturization after two months of using minoxidil and spironolactone. Specific treatments mentioned are minoxidil and spironolactone.
The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The user transitioned from finasteride to Cyproterone and started using Minoxidil, resulting in healthier hair and regrowth. They plan to wean off Minoxidil in a year, depending on regrowth.
User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.
User "al_ick" shares progress with topical fin, min, tret, and micro needling for hair loss, showing good results. They use hims fin and min combination spray, applying 5-7 sprays for better coverage.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.
The conversation discusses using a dermastamp for microneedling to treat hair loss, focusing on needle length and frequency. Users share their routines, including applying minoxidil after microneedling, with some waiting 24 hours to avoid side effects.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The user has been using finasteride for years with little regrowth and recently started using Cécred edge drops, which have significantly improved their scalp condition. Another user mentioned combining Cécred with derma stamping for better results.